secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001193125-23-278334
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology Medicines to merge with Q32 Bio, valuing Q32 at $195M; CEO and CFO terminated
--------------------------------------------------------------------------------

- All-stock merger ascribes Q32 equity value of $195M; Homology equity ~$80M; Q32 stockholders to receive Homology common shares.
- Q32 to raise $42M in concurrent financing from accredited investors immediately before close.
- Combined board to have 9 members: 2 from Homology, 7 from Q32 (indicating Q32 control).
- Q32 holders with 74.1% of Q32 capital stock and Homology holders with 18.2% of common stock support deal via support agreements.
- CEO Albert Seymour and CFO W. Bradford Smith terminated; Paul Alloway named President/COO/PEO; Charles Michaud named VP/Controller/Treasurer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/d350392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-278334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer